Tuoxin Pharmaceutical Group Co (SZSE:301089) Cash-to-Debt : No Debt ⁽¹⁾ (As of Sep. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Tuoxin Pharmaceutical Group Co Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Tuoxin Pharmaceutical Group Co's cash to debt ratio for the quarter that ended in Sep. 2023 was No Debt ⁽¹⁾.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Tuoxin Pharmaceutical Group Co could pay off its debt using the cash in hand for the quarter that ended in Sep. 2023.

(1) Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

The historical rank and industry rank for Tuoxin Pharmaceutical Group Co's Cash-to-Debt or its related term are showing as below:

SZSE:301089' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.46 Med: 0.93 Max: No Debt
Current: 35.15

During the past 9 years, Tuoxin Pharmaceutical Group Co's highest Cash to Debt Ratio was No Debt. The lowest was 0.46. And the median was 0.93.

SZSE:301089's Cash-to-Debt is ranked better than
84.64% of 1048 companies
in the Drug Manufacturers industry
Industry Median: 0.95 vs SZSE:301089: 35.15

Tuoxin Pharmaceutical Group Co Cash-to-Debt Historical Data

The historical data trend for Tuoxin Pharmaceutical Group Co's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Tuoxin Pharmaceutical Group Co Cash-to-Debt Chart

Tuoxin Pharmaceutical Group Co Annual Data

Trend

Dec12

Dec13

Dec14

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Cash-to-Debt

Get a 7-Day Free Trial

0.91

0.68

0.94

7.27

13.67

Tuoxin Pharmaceutical Group Co Quarterly Data
	Dec14	Jun15	Dec17	Dec18	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Cash-to-Debt	Get a 7-Day Free Trial															5.88	13.67	61.33	No Debt	No Debt

Competitive Comparison of Tuoxin Pharmaceutical Group Co's Cash-to-Debt

For the Drug Manufacturers - Specialty & Generic subindustry, Tuoxin Pharmaceutical Group Co's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Tuoxin Pharmaceutical Group Co's Cash-to-Debt Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Tuoxin Pharmaceutical Group Co's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Tuoxin Pharmaceutical Group Co's Cash-to-Debt falls into.

Tuoxin Pharmaceutical Group Co Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Tuoxin Pharmaceutical Group Co's Cash to Debt Ratio for the fiscal year that ended in Dec. 2022 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	547.25	/	(40.034	+	0)
	=	13.67

Tuoxin Pharmaceutical Group Co's Cash to Debt Ratio for the quarter that ended in Sep. 2023 is calculated as:

Tuoxin Pharmaceutical Group Co had no debt ⁽¹⁾.

Tuoxin Pharmaceutical Group Co (SZSE:301089) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Tuoxin Pharmaceutical Group Co Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Tuoxin Pharmaceutical Group Co's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Tuoxin Pharmaceutical Group Co (SZSE:301089) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Tuoxin Pharmaceutical Group Co Ltd (SZSE:301089) » Definitions » Cash-to-Debt

Traded in Other Exchanges

N/A

Address

No. 398, Jingquan West Road, High-tech Zone, Henan Province, Xinxiang, CHN, 453000

Website

http://www.tuoxinpharm.com

Tuoxin Pharmaceutical Group Co Ltd, formerly Xinxiang Tuoxin Pharmaceutical Co Ltd is engaged in the research and development, production and sales of chemical synthesis and biological fermentation nucleoside APIs and pharmaceutical intermediates.

Tuoxin Pharmaceutical Group Co (SZSE:301089) Headlines

No Headlines

Tuoxin Pharmaceutical Group Co (SZSE:301089) Cash-to-Debt : No Debt (1) (As of Sep. 2023)